|
1
|
Guglielmi A, Ruzzenente A, Conci S, et al:
Hepatocellular carcinoma: Surgical perspectives beyond the
barcelona clinic liver cancer recommendations. World J
Gastroenterol. 20:7525–7533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Shi ZL, Yang X and Yin ZF:
Targeting of circulating hepatocellular carcinoma cells to prevent
postoperative recurrence and metastasis. World J Gastroenterol.
20:142–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shindoh J, Kaseb A and Vauthey JN:
Surgical strategy for liver cancers in the era of effective
chemotherapy. Liver Cancer. 2:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao X, Ogunwobi OO and Liu C: Survivin
inhibition is critical for Bcl-2 inhibitor-induced apoptosis in
hepatocellular carcinoma cells. PLoS One. 6:e219802011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu JL, Zhang XJ, Zhang Z, Zhang AH, Wang
W and Dong JH: Meta-analysis: Prognostic value of survivin in
patients with hepatocellular carcinoma. PLoS One. 8:e833502013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheung CH, Huang CC, Tsai FY, et al:
Survivin - biology and potential as a therapeutic target in
oncology. Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamanaka K, Nakata M, Kaneko N, et al:
YM155, a selective survivin suppressant, inhibits tumor spread and
prolongs survival in a spontaneous metastatic model of human triple
negative breast cancer. Int J Oncol. 39:569–575. 2011.PubMed/NCBI
|
|
8
|
Tao YF, Lu J, Du XJ, et al: Survivin
selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor
cells. BMC Cancer. 12:6192012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai PC, Chen SH, Yang SH, Cheng CC, Chiu
TH and Huang YT: Novel survivin inhibitor YM155 elicits
cytotoxicity in glioblastoma cell lines with normal or deficiency
DNA-dependent protein kinase activity. Pediatr Neonatol.
53:199–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang H, Zhang L, Xu R and Ju XL:
Silencing of survivin using YM155 induces apoptosis and
chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol
Sci. 17:2909–2915. 2013.PubMed/NCBI
|
|
11
|
Koike H, Nitta T, Sekine Y, et al: YM155
reverses rapamycin resistance in renal cancer by decreasing
survivin. J Cancer Res Clin Oncol. 140:1705–1713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Jiang S, Zhang Y, et al: High
expression of thymosin beta 10 predicts poor prognosis for
hepatocellular carcinoma after hepatectomy. World J Surg Oncol.
12:2262014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Charette N, De Saeger C, Horsmans Y,
Leclercq I and Stärkel P: Salirasib sensitizes hepatocarcinoma
cells to TRAIL-induced apoptosis through DR5 and survivin-dependent
mechanisms. Cell Death Dis. 4:e4712013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reed CA, Mayhew CN, McClendon AK, Yang X,
Witkiewicz A and Knudsen ES: RB has a critical role in mediating
the in vivo checkpoint response, mitigating secondary DNA damage
and suppressing liver tumorigenesis initiated by aflatoxin B1.
Oncogene. 28:4434–4443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nojiri S and Joh T: Albumin suppresses
human hepatocellular carcinoma proliferation and the cell cycle.
Int J Mol Sci. 15:5163–5174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaneko N, Mitsuoka K, Amino N, et al:
Combination of YM155, a survivin suppressant, with bendamustine and
rituximab: A new combination therapy to treat relapsed/refractory
diffuse large B-cell lymphoma. Clin Cancer Res. 20:1814–1822. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fabregat I: Dysregulation of apoptosis in
hepatocellular carcinoma cells. World J Gastroenterol. 15:513–520.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Coumar MS, Tsai FY, Kanwar JR, Sarvagalla
S and Cheung CH: Treat cancers by targeting survivin: Just a dream
or future reality? Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rauch A, Hennig D, Schäfer C, et al:
Survivin and YM155: How faithful is the liaison? Biochim Biophys
Acta. 1845:202–220. 2014.PubMed/NCBI
|
|
21
|
Zeng J, Sun Y, Wu K, et al:
Chemopreventive and chemotherapeutic effects of intravesical
silibinin against bladder cancer by acting on mitochondria. Mol
Cancer Ther. 10:104–116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang R, Humphreys I, Sahu RP, Shi Y and
Srivastava SK: In vitro and in vivo induction of apoptosis by
capsaicin in pancreatic cancer cells is mediated through ROS
generation and mitochondrial death pathway. Apoptosis.
13:1465–1478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taniguchi H, Horinaka M, Yoshida T, et al:
Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer
cells by downregulating the expression of antiapoptotic molecules.
Mol Cancer Ther. 11:2294–2300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakai T, Eskander RN, Guo Y, et al:
Flavokawain B, a kava chalcone, induces apoptosis in synovial
sarcoma cell lines. J Orthop Res. 30:1045–1050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Loor G, Kondapalli J, Iwase H, et al:
Mitochondrial oxidant stress triggers cell death in simulated
ischemia-reperfusion. Biochim Biophys Acta. 1813:1382–1394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baker SJ and Reddy EP: CDK4: A key player
in the cell cycle, development and cancer. Genes Cancer. 3:658–669.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu H, Li Z, Chen J, et al: P16
reactivation induces anoikis and exhibits anti tumour potency by
down regulating Akt/survivin signalling in hepatocellular carcinoma
cells. Gut. 60:710–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng L, Lu Y, Zhao X, et al: Ran GTPase
protein promotes human pancreatic cancer proliferation by
deregulating the expression of Survivin and cell cycle proteins.
Biochem Biophys Res Commun. 440:322–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
